AG
JNCE

Advisor Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Advisor Group’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Buy
+100
New +$540 ﹤0.01% 5236

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Advisor Group's JNCE Position: Q4 2019 in Review

Advisor Group opened a new position in Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2019: 100 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #5236 among its holdings.

100 funds tracked by Wall St. Rank hold JNCE as of Q4 2019.

  • Advisor Group held 100 shares of Jounce Therapeutics, Inc. Common Stock worth $1K as of Q4 2019.
  • Jounce Therapeutics, Inc. Common Stock was a new Advisor Group position in Q4 2019.
  • Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5236 holding.
  • 100 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.